Document:

<PAGE>

                                                                    EXHIBIT 10.6

                                                                REDACTED VERSION

  *** Confidential treatment has been requested as to certain portions of this
  agreement.  Such omitted confidential information has been designated by an
    asterisk and has been filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as
   amended, and the Commission's rules and regulations promulgated under the
Freedom of Information Act, pursuant to a request for confidential treatment.***

                                   AGREEMENT

     THIS AGREEMENT ("Agreement") is made and entered into as of the 21st day of
October, 1999, by and between AMPC, Inc., an Iowa corporation (the "Company"),
and SeraCare, Inc., a California corporation, with its principal place of
business at 1935 Avenida del Oro, Suite F, Oceanside, California ("SeraCare").

RECITALS:

A.   SeraCare desires to be appointed as the Company's exclusive independent
     representative to market and promote the sale of certain Products (as that
     term is defined below) of the Company in the Territory (as that term is
     defined below), and hereby represents to the Company that the nature of its
     existing and ongoing business and the experience of its personnel are such
     that SeraCare is qualified to perform and fulfill such activities as
     provided herein.

B.   Although the Company desires to appoint SeraCare as its exclusive
     independent representative in the Territory, the Company is willing to do
     so only upon the condition that it define SeraCare's relationship with the
     Company and secure certain covenants which SeraCare hereby acknowledges are
     necessary and appropriate to protect the business of the Company.

C.   The Company and SeraCare desire to establish their relationship and such
     covenants upon the terms and conditions set forth herein.

     NOW, THEREFORE, in consideration of the Recitals and the mutual agreements
set forth herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto agree as
follows:

    1. Products. For purposes of this Agreement, the term "Products" shall mean
only those products which are specifically described in Schedule 1 as attached
hereto from time to time and signed by the parties. Notwithstanding any term or
condition herein or otherwise which may appear to be to the contrary, the
Company shall have the right, upon providing SeraCare with ninety (90) days
prior written notice, to discontinue the marketing and sale of any or all of the
Products or combinations of the Products in the Territory, and shall otherwise
have the unqualified right to manage its business in all respects, including,
without limitation, making all decisions with respect to altering the
composition of any Product, the warranties made with respect to any Product (if
any), and the labeling or packaging of any Product.
<PAGE>

    2. Appointment; Excluded Customers. The Company hereby appoints SeraCare, as
an independent representative acting in its own name, and SeraCare hereby
accepts such appointment, as the Company's exclusive representative to market,
promote the sale of and sell the Products to persons and entities which use the
Products to manufacture diagnostic test kits, assays and chemical solutions for
clinical chemistry for humans throughout the World (the "Territory"); provided,
however, all upon the terms and conditions set forth herein. SeraCare shall have
no right to market or sell any Products to any person or entity (i) identified
in Schedule 2 attached hereto, or (ii) engaged, directly or indirectly, in the
veterinary vaccine market (collectively, the "Excluded Customers"). SeraCare
acknowledges and agrees that the Company or any agent or representative of the
Company may market and sell Products to the Excluded Customers without the
payment of any commissions or fees under this Agreement. In addition to the
foregoing, SeraCare shall not market or sell any Products to any person or
entity engaged, directly or indirectly, in the activity or business of injecting
or otherwise administering the Products directly into humans or animals.

     SeraCare may, on a non-exclusive basis, market, promote the sale of and
sell the Products to persons and entities engaged, directly or indirectly, in
(i) the laboratory growth of cell and/or microbe cultures for the production of
proteins and/or vaccines for human use, and/or (ii) life science research,
unless otherwise agreed to in writing by both parties hereto.

    3.  Inquiries from Potential Customers.  In the event the Company receives,
during the term of this Agreement, inquiries from potential purchasers to whom
SeraCare has the exclusive right to sell the Products as provided in paragraph 2
above, the Company will provide the names of such potential purchasers to
SeraCare.

    4.  Manner of Sales.  Unless otherwise expressly agreed by the parties, each
order requesting any Product shall be filled by a sale of the requested Product
by the Company to SeraCare.  In all events, however, all orders for Products
shall be subject to approval and acceptance by the Company and to and upon all
of the Company's rules, regulations, procedures and policies, including, without
limitation, its requirements as to order forms and the content thereof, its
credit policies and all other terms and conditions of sale, all of which Company
may change at any time and from time to time, in its sole discretion.

     Title and risk of loss of the Products shall pass from Company to SeraCare
when the Products are shipped from the Company's facilities.  SeraCare shall be
responsible for determining that each lot of the Products conforms to the
certificate of analysis provided for that lot.  SeraCare must notify Company in
writing of the following defects in any delivery of the Products within the
following time limits:

     (i)  Damage or non-delivery of any part of any order -- within five (5)
          business days of SeraCare's receipt of the Product, or

     (ii) Product non-compliance with certificate of analysis -- within fifteen
          (15) business days of SeraCare's receipt of the Product, with a copy
          of the Product test results made by SeraCare on which notice of
          failure to comply is based.

                                      -2-
<PAGE>

The notice date of SeraCare's non-acceptance shall be the date of notice to the
Company specifying the defect in delivery.

    If Company disagrees with SeraCare's reasons for non-compliance, Company
may request re-testing of the Product in question by an independent laboratory
for verification of SeraCare's reasons for non-acceptance.  Company shall bear
the costs for any such re-testing.  In the event the Product in question is
found by the independent laboratory to be in conformance with the Specifications
(as hereinafter defined), then SeraCare shall accept the shipment and fully
reimburse Company for all costs incurred in connection with the re-testing.

    5. Minimum Purchases by SeraCare; Requirements Contract. SeraCare agrees
that it shall purchase from Company no less than *** kg per month of the
Products for the first*** of this Agreement, *** kg per month of the Products
in the second *** of this Agreement and *** kg per month of the Products in the
third *** of this Agreement (the "Minimum Required Purchase Amount"), providing
such quantities are delivered and accepted by SeraCare in accordance with
paragraph 4.

     During the term of this Agreement, SeraCare shall purchase all of its
requirements of Products only from the Company and shall not purchase or
otherwise acquire Products from any person or entity other than the Company;
provided, however, in the event the Company notifies SeraCare at any time, or
from time to time, during the term of this Agreement, that it is unable to
supply all of SeraCare's requirements of the Products, SeraCare may purchase
from other sources such amount of Products the Company is unable to supply;
further provided, however, that when the Company notifies SeraCare it is again
able to supply some or all of SeraCare's requirements, SeraCare shall again
purchase all of its requirements of Products, or so much of the Products as the
Company is then able to supply to SeraCare, only from the Company.

    6. Additional Duties of SeraCare. SeraCare agrees to devote its best efforts
and such time as is necessary or appropriate to diligently market, promote the
sale of and sell the Products in the Territory. Without limiting the generality
of the foregoing, and in addition thereto, SeraCare agrees that it will use its
best efforts to:

    (a) Bring the Products of the Company to the attention of all individuals or
        entities of any nature in the Territory who qualify as customers of
        Product within the definition in paragraph 2, and who may reasonably be
        determined to be prospective purchasers of any or all of the Products.

    (b) Contact, on a periodic basis, all existing individuals or entities who
        qualify as customers of Product within the definition in paragraph 2 and
        who are purchasing any Products in the Territory, to promote continued
        and further purchases of the Products and to assure that all such
        existing customers are satisfied with the Products and the service being
        provided to them.

    (c) Maintain complete, accurate and up-to-date records of its efforts under
        this Agreement, including, without limitation: (i) records setting forth
        the names and addresses of all individuals and entities contacted by
        SeraCare regarding any
---------------------
*** Confidential information omitted and filed separately with the Securities
    and Exchange Commission.

                                      -3-
<PAGE>

        Products; (ii) a general record of all discussions with such individuals
        and entities; and (iii) copies of all correspondence to and from such
        persons and entities.

    (d) Handle to the satisfaction of any potential or existing customer, and on
        a same-day basis, any orders or any questions or problems relating to
        the Products or other services being or to be provided to the customer,
        and advise all potential or existing customers to contact the Company
        regarding such questions or problems and in all events to promptly
        notify an appropriate representative of the Company of any such
        questions or problems when necessary or appropriate.

    (e) Comply at all times with all applicable laws, rules, regulations,
        ordinances and orders.

    (f) obtain and continuously maintain in effect any and all governmental or
        other approvals, authorizations, registrations, licenses or permits, if
        any, which are necessary or appropriate for SeraCare to fully and timely
        perform all of its obligations hereunder, including, without limitation,
        obtaining and maintaining in effect all registrations of the Products
        and approvals of this Agreement in the Territory as provided for in
        paragraph 10 below. SeraCare shall provide evidence of all of the same
        to the Company from time to time upon the request of thee Company.

    (g) Immediately advise the Company in writing or any matters with respect to
        any Product which come to the attention of SeraCare and which may raise
        an issue of compliance of the Product with applicable local, provincial,
        state, federal or other governmental law, rule or regulation of the
        Territory, and how such matters can be resolved, including, without
        limitation, with respect to the packaging or labeling thereof; provided,
        however, that the Company shall be responsible for all costs and
        expenses necessary to resolve such matters in the event Company
        determines, in its sole discretion, to resolve such matters. SeraCare
        shall have the right to discontinue marketing the Product should the
        Company choose to not resolve any bona fide legal matter raised by
        SeraCare with respect thereto, but such discontinuance shall not
        otherwise affect any term or condition hereof or obligation of SeraCare
        hereunder with respect to any other Products, and the Company may in
        such event, in its sole discretion, terminate this Agreement upon sixty
        (60) days written notice to SeraCare.

    (h) Not engage in any unethical, illegal, deceptive, fraudulent or
        misleading activities in connection with the performance of any services
        hereunder, including, without limitation, providing any deceptive,
        fraudulent, misleading, false or incorrect information to the Company or
        any Affiliate (as that term is hereinafter defined), any potential or
        existing customer, or any third party dealing with the Company or any
        Affiliate of any customer, and whether about the Products or otherwise.

    (i) Engage, at the sole expense of SeraCare, a sufficient number of
        personnel to properly canvas the Territory and to assist in the
        performance of all other services required of SeraCare hereunder. All
        such personnel shall be employees, agents or

                                      -4-
<PAGE>

        independent contractors of SeraCare and not of the Company, and shall be
        bound by all of the terms and conditions of this Agreement. SeraCare
        shall be responsible and liable for assuring full compliance by such
        personnel with all of the terms and conditions of this Agreement.

    (j) Recognize, both during and after the term of this Agreement, and without
        limiting paragraphs 13 and 14 below, the exclusive right and ownership
        of the Company in and to all names, trade names, trade or service marks,
        patents, copyrights and all other intellectual properties used by the
        Company in connection with the Products and Company's business, and to
        market and sell the Products only under the trade or service marks and
        trade names regularly applied to them by the Company and otherwise in
        accordance with paragraph 13 below.

    (k) Not do or say any act or thing, or omit to do or say any act or thing,
        during the term of this Agreement or at any time thereafter, which may
        impair, damage, or destroy the goodwill or reputation of the Products,
        the Company or any of its Affiliates, or that is detrimental to the
        Company or any of its Affiliates or their respective businesses.

    (l) Make no promises, representations or commitments which are not within
        the authority granted to SeraCare hereunder, including, without
        limitation, making any warranties or promises to customers with respect
        to the condition, quality, composition, capabilities or otherwise of any
        Products which are not specifically made or given in writing by the
        Company (if any) to its other customers.

    (m) Provide all customers with only those written promotional and sales
        materials, including, without limitation, price sheets and order forms,
        which have been either provided by the Company or otherwise previously
        approved by the Company pursuant to subparagraph (n) immediately below.

    (n) Submit all proposed advertising materials relating to the Products to
        the Company for the Company's approval, prior to dissemination of any of
        the same, and to utilize only such advertising materials as are
        expressly approved by the Company, in its sole discretion, in writing.

    (o) SeraCare will provide copies of quarterly and annual financial
        statements on Form 10Q and/or Form 10K within a reasonable period after
        having filed such reports with the Securities and Exchange Commission.
        All financial information submitted by SeraCare shall be true and
        accurate in all material respects.

    (p) Submit to Company after completion of the first three (3) months of this
        Agreement a written forecast for the quantities of the Products expected
        to be required in excess of the Minimum Required Purchase Amount, if
        any, for the ensuing three (3) months, and thereafter update this
        forecast on a monthly basis. It is understood that the quantities of the
        Products specified in the first two (2) months of each forecast are
        binding on SeraCare, whereas the remainder are non-binding estimates of
        SeraCare's projected purchases of the Products in excess

                                      -5-
<PAGE>

        of the Minimum Required Purchase Amount. Company will respond within ten
        (10) days of each request as to the status of production and ability to
        supply the amounts in excess of the Minimum Required Purchase Amount.

    (q) SeraCare will submit to Company at least one (1) month prior to each
        desired shipment date a written purchase order for delivery of
        SeraCare's intended purchases in excess of the Minimum Required Purchase
        Amount, if any.

    7.  Duties of the Company.  The Company agrees to:

    (a) Provide sales and technical assistance to SeraCare similar to that
        provided by the Company to its other independent sales agents in the
        United States, if any.

    (b) Furnish SeraCare with a reasonable amount of such promotional and sales
        materials (in the English language) as the Company, in its sole
        discretion, generally prepares in regard to the Products.

    (c) Upon receiving written approval by SeraCare, the Company may identify
        SeraCare in the Company's promotional materials.

    (d) Sell Products to SeraCare as provided herein, use its best efforts to
        ship the Products on the shipment dates specified on SeraCare's purchase
        orders, and advise SeraCare of any inability to make full and timely
        shipment of the Products which SeraCare has ordered; provided, however,
        that the Company shall not be liable for any loss or damage caused by
        its nonacceptance or delay in acceptance of orders submitted by SeraCare
        which are not in compliance with all applicable procedures, policies,
        rules and regulations of the Company, nor for failure or delay in
        meeting any order of SeraCare or in performing any other duty or
        obligation hereunder arising from or in any way related to (i) any
        governmental restriction or any other act of God or Force Majeure (as
        hereinafter defined) or other occurrence or nonoccurrence beyond the
        reasonable control of the Company, or (ii) from or to any capacity or
        production limitations affecting the Company or any of its Affiliates or
        any failures or delays (for whatever reason) by any vendors or suppliers
        of the Company or any of its Affiliates, with the Company reserving the
        right to allocate its Products and services in such amounts and manner
        as it deems appropriate, in its discretion. Notwithstanding anything
        contained in this Agreement which may appear to be to the contrary, the
        Company will have no liability or obligation to SeraCare as a result of
        the Company's failure or inability to supply Products to SeraCare under
        this Agreement.

    (e) Perform quality control on each lot of the Products supplied to SeraCare
        in accordance with Company's then current internal procedures and
        provide SeraCare with certificates of analysis and certificates of
        origin confirming the compliance of each lot of the Products with the
        specifications identified in Schedule 1 (the "Specifications").

                                      -6-
<PAGE>

    (f) Store properly a sample of each lot of the Products, until the
        expiration date of such lot, or as required under cGMP Guidelines, to
        enable subsequent verification of the lot's conformance with the
        Specifications.

    (g) Provide SeraCare with training on the characteristics and uses of the
        Products and thereafter provide all reasonable assistance required by
        SeraCare to answer questions from SeraCare's customers or personnel
        regarding the use, handling or technical aspects or the Products.
        SeraCare agrees to reimburse Company for reasonable travel and hotel
        expenses incurred by Company in connection with its responsibilities
        under this subparagraph (g).

    (h) Permit SeraCare's customers to inspect Company's facilities pursuant to
        a confidentiality agreement acceptable to Company and with a minimum of
        one (1) month prior written notice. Company reserves the right to refuse
        inspection of its facilities by any company it perceives to be a
        competitor or potential competitor in the Bovine Serum Albumin or other
        Company markets.

    (i) Comply at all times with all applicable laws, rules, regulations,
        ordinances and orders of the FDA, USDA, or cGMP as applicable.

    8.  Disclaimer of Warranties; Statute of Limitations; Remedies.  COMPANY
REPRESENTS AND WARRANTS TO SERACARE THAT: (I) THE PRODUCTS SOLD TO SERACARE
HEREUNDER WILL BE SHIPPED IN CONFORMITY WITH THE SPECIFICATIONS AND WILL BE FREE
FROM DEFECTS IN MATERIALS AND WORKMANSHIP; AND (II) THE PRODUCTS SOLD TO
SERACARE WILL BE MANUFACTURED, PACKAGED, LABELED, STORED AND SHIPPED IN
CONFORMITY WITH ALL APPLICABLE U.S. FEDERAL, UNITED STATES AND LOCAL LAWS AND
REGULATIONS APPLICABLE AT THE COMPANY'S LOCATION FROM WHICH THE PRODUCTS ARE
SHIPPED TO SERACARE.  EXCEPT FOR SUCH WARRANTIES, THE COMPANY MAKES NO EXPRESS
WARRANTIES, AND HEREBY EXCLUDES AND DISCLAIMS IN ENTIRETY ALL IMPLIED
WARRANTIES, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO ANY
PRODUCTS PROVIDED BY THE COMPANY.  IN NO EVENT SHALL THE COMPANY BE LIABLE FOR
ANY LOST PROFITS, EXEMPLARY, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES
WHATSOEVER ARISING OUT OF THIS AGREEMENT (EVEN IF THE COMPANY HAS BEEN ADVISED
OF THE POSSIBILITY OF SUCH DAMAGES), INCLUDING, WITHOUT LIMITATION, ANY LOST
PROFITS, EXEMPLARY, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF
THE PERFORMANCE OR NONPERFORMANCE BY THE COMPANY UNDER THIS AGREEMENT OR ANY
PRODUCTS OR ARISING OUT OF THE USE OF OR INABILITY TO USE THE PRODUCTS OR ANY
OTHER GOODS OR PRODUCTS FOR ANY REASON AND FOR ANY PURPOSE WHATSOEVER.  ANY
ACTION FOR BREACH OF ANY TERM OF THIS AGREEMENT MUST BE COMMENCED WITHIN ONE (1)
YEAR AFTER THE DATE THE CAUSE OF ACTION ACCRUES.

                                      -7-
<PAGE>

     SeraCare will include the above provisions in the terms and conditions of
all sales of the Products by SeraCare.

     In the event that a shipment of the Products from Company to SeraCare has
not been delivered in full, and if written notice thereof is duly given to
Company as provided in paragraph 4, Company's sole liability and responsibility
to SeraCare shall be to rectify such default as soon as shall be reasonably
practicable by delivery, at Company's expense, of a replacement of the missing
quantity of the Products.

     In the event that a Product supplied to SeraCare by Company fails to comply
with the provided certificate of analysis, and if written notice thereof is duly
given to Company as provided in paragraph 4, SeraCare shall return to Company,
at Company's expense, the product lot in question or dispose of said lot
according to Company's instructions, whereupon Company's sole liability and
responsibility to SeraCare shall be to replace an equivalent supply of the
Products at its own expense, as soon as shall be reasonably practicable.

    9. Prices for Products. In consideration for the Products, SeraCare shall
pay Company the transfer prices indicated in the attached Schedule 3, FOB Ames,
Iowa, unless otherwise mutually agreed by the parties in writing. Such transfer
prices shall be paid to Company by SeraCare within thirty (30) days of the date
of invoice of each shipment of the Products, unless the Products are not
accepted by SeraCare pursuant to the terms of paragraph 4. All payments made by
SeraCare shall be made in U.S. dollars.

     In connection with SeraCare's efforts to market the Products, SeraCare may,
from time to time, request from Company in writing temporary special pricing for
the Products.  Company agrees to notify SeraCare in writing within fifteen (15)
days of receipt of any such request of the pricing, terms and conditions under
which Company is willing, to sell the Products to SeraCare.  Any grant of
temporary special pricing by Company to SeraCare shall not be construed to waive
the terms and conditions of this paragraph 9.

     Company and SeraCare have determined *** for the Products *** on the
Product, as set forth in Schedule 3 hereto.  ***

     The transfer prices and *** set forth in Schedule 3 are firm for the
Products ordered during the first *** of this Agreement.  Prior to the
commencement of the *** period of this Agreement, the Company and SeraCare will
negotiate concerning the transfer prices and the ***during the second ***
period of this Agreement; provided, however, if the Company and SeraCare are
unable to mutually agree prior to the commencement of such second *** period,
the transfer prices and *** for the second *** period of this Agreement will
automatically increase by *** over the prices in effect for the first ***
period.  Prior to the commencement of the third *** period of this Agreement,
the Company and SeraCare will negotiate concerning the transfer prices ***
period of this Agreement; provided, however, if the Company and SeraCare are
unable to mutually agree prior to the commencement of such third *** period, the
transfer prices and *** for the third *** period of this Agreement will
automatically increase by *** over the prices in effect for the second
***period.
------------------------

*** Confidential information omitted and filed separately with the Securities
and Exchange Commission.

                                      -8-
<PAGE>

     SeraCare shall supply to Company a quarterly accounting of sales prices and
volumes and shall make payment on profit sharing to Company within thirty (30)
days of the close of each quarter.  Company shall have full access to such sales
records and shall have the opportunity, at its expense, to audit or verify the
same.  SeraCare shall, however, reimburse Company for its costs in the event
Company's audit or verification discloses any material error in SeraCare's sales
reports to the Company.

    10. Expenses. SeraCare agrees that it shall pay and be solely responsible
for all costs and expenses of any nature whatsoever which are incurred by
SeraCare in rendering services pursuant to this Agreement, and that the Company
shall not be responsible for any such costs and expenses. SeraCare further
agrees that it shall pay and be solely responsible for the cost of registration
of the Products within the Territory and for obtaining all necessary Territory
governmental approvals of this Agreement and the Products, if any, and for
maintaining all of the same during the term of this Agreement: provided,
however, that SeraCare will notify Company in writing at least thirty (30) days
prior to applying for any such registration and/or approvals of the Products.
SeraCare shall provide copies of any such registrations and/or approvals to the
Company upon request of the Company from time to time. All such registrations
shall be in the name of the Company, unless otherwise affirmatively required by
the applicable governmental authority in the Territory, but any such
registration in the name of SeraCare shall not operate to grant any rights to
SeraCare in the Products.

    11.  Term and Termination.

     (a) The term of this Agreement shall be for a period of three (3) years
         from the date hereof, and shall be automatically renewed thereafter for
         successive one (1) year periods, unless either party provides written
         notice to the other of its intention not to renew this Agreement, for
         whatever reason, with or without cause, at least one hundred eighty
         (180) days prior to the termination date of the term then in effect, or
         this Agreement is earlier terminated pursuant to any other provision of
         this Agreement; provided, however, if SeraCare and Company cannot
         mutually agree as to the Minimum Required Purchase Amount, the transfer
         prices and/or the *** for such renewal term at least ninety (90) days
         prior to the termination of the term then in effect, then this
         Agreement shall automatically terminate at the end of the term then in
         effect.

     (b) This Agreement may be terminated by the Company, at its option,
         effective sixty (60) days following the giving of notice thereof to
         SeraCare, in the event SeraCare shall have failed to meet the Minimum
         Required Purchase Amount for any calendar quarter.

     (c) This Agreement may be terminated by ether party in the event of any
         breach or nonfulfillment of or default under any term or condition of
         this Agreement by the other party, which breach, nonfulfillment or
         default is not fully cured by the applicable party (if capable of cure)
         within sixty (60) days following the giving of written notice thereof
         by the other party; provided, however, that this Agreement shall
         terminate immediately and without opportunity for cure by SeraCare

------------------------
*** Confidential information omitted and filed separately with the Securities
and Exchange Commission.

                                      -9-
<PAGE>

         (i) upon receipt by SeraCare of notice of termination from the Company
         in the event of a breach or nonfulfillment of or default by SeraCare
         under paragraphs 6(e), 6(f), 6(i), 13, 14 or 16 hereof; or (ii) upon
         the dissolution or liquidation of, termination of existence of,
         insolvency of, business failure of, appointment of receiver of any part
         of the property of, assignment for the benefit of creditors by, or the
         commencement of any proceeding (whether voluntary or involuntary) under
         any bankruptcy, insolvency, debtor-creditor, receivership or similar or
         related law by or against SeraCare.

    12. Transactions After Termination. In addition to any other provisions
hereof addressing the rights or obligations of the parties upon the termination
of this Agreement, the parties agree that upon the termination of this
Agreement, for whatever reason:

     (a) SeraCare shall return all written promotional, advertising and sales
         materials provided to SeraCare by the Company hereunder.

     (b) Notwithstanding anything herein or otherwise which may appear to be to
         the contrary, the termination of this Agreement shall not affect any
         liability or obligation of the parties hereunder which shall accrue
         prior to such termination, including, but not limited to, any liability
         for loss or damage or on account of breach, nor shall the termination
         of this Agreement (by either party and for whatever reason) affect the
         terms or provisions hereof which contemplate performance by or
         continuing obligations of a party beyond the termination hereof,
         including, without limitation, the obligations of SeraCare under
         paragraphs 6(i), 6(j), 14, 15, 16 and 20 hereof, all which shall
         continue in effect notwithstanding any termination hereof.

    13.  Trademarks of the Company.  SeraCare is hereby granted a limited,
nonassignable and nontransferable right to use the Company's trade or service
marks and trade names related to the Products in distributing, advertising and
promoting the sale of the Products, but only in strict accordance with the
Company's policies regarding the use of its trade or service marks and trade
names.  The rights conferred herein shall cease and terminate immediately,
without notice, upon the termination of this Agreement, and SeraCare agrees to
take, at its sole cost and expense, all such steps as are necessary or
appropriate to cease all use of the Company's trade or service marks and trade
names in such event.  Notwithstanding anything herein or otherwise which may
appear to be to the contrary, the Company's trade or service marks and trade
names shall at all times be and remain the sole and exclusive property of the
Company, and the Company reserves all rights in and to the same.  SeraCare
agrees to use its best efforts to notify the Company of any and all
infringements of the Company's trade or service marks or trade names pertaining
to the Products which may come to SeraCare's attention during the term hereof
and to assist the Company in taking such action against said infringement as the
Company, in its sole discretion, may decide.

    14.  Proprietary and Confidential Information.

     (a) SeraCare acknowledges and agrees that it is necessary for the Company
         to prevent the unauthorized use and disclosure of Proprietary and
         Confidential Information

                                      -10-
<PAGE>

         (defined below) regarding the Company and its Products and business.
         Accordingly, and in further consideration for this Agreement, SeraCare
         covenants and agrees that SeraCare will not, during the term of this
         Agreement or at any time thereafter (whether this Agreement is
         terminated by Company, by SeraCare or by mutual consent, and for
         whatever reason), directly or indirectly, engage in or take or refrain
         from taking any action or inaction which may in any way lead to the use
         or disclosure of any Proprietary and Confidential Information regarding
         the Company, its Products or its business by or to any third party, nor
         use or disclose any such Proprietary and Confidential Information for
         SeraCare's own benefit excepting only such limited disclosures or use
         by SeraCare during the term of this Agreement as are both expressly
         authorized in connection with SeraCare's services hereunder and are
         also otherwise necessary, proper and lawful. SeraCare further
         acknowledges and agrees that the Company reserves the right to
         determine, in the Company's sole discretion, what information (whether
         Proprietary and Confidential Information or otherwise) regarding the
         Company, its Products or its business shall be disclosed to SeraCare
         from time to time.

     (b) For purposes of this Agreement, "Proprietary and Confidential
         information" shall mean all information in any form which is
         proprietary and confidential to the Company, its Products or its
         business, whether received, obtained or compiled by SeraCare after the
         date hereof and whether or not designated as such when received or
         obtained by SeraCare, and shall include, but not be limited to, the
         following types of information: (i) corporate information, including
         contractual arrangements (including the terms of this Agreement),
         plans, strategies, tactics, policies and resolutions; (ii) any
         litigation or negotiations; (iii) marketing information of the Company,
         including price lists, sales or product plans, strategies or methods:
         (iv) market research data of the Company, including any prepared by
         SeraCare in performing hereunder; (v) financial information of the
         Company, including cost and performance data, debt arrangement, equity
         structure, investors, and holdings; (vi) operational information of the
         Company, including trade secrets, control and inspection practices,
         suppliers and vendors, all information related to products and products
         lines, formulas, formulations, processes, and know-how or any
         copyrights, patents or other intellectual properties utilized by the
         Company; (vii) personnel information of the Company, including
         personnel lists, resumes, personal data, organizational structure and
         performance evaluations; (viii) information provided to or obtained in
         any way by the Company under restrictions as to use, reproduction or
         further disclosure; and (ix) information provided to or obtained in any
         way by the Company regarding another person, corporation or other form
         of entity which owns or controls the Company, or which is owned or
         controlled by the Company or under common control with the Company
         (collectively, the "Affiliates"), and which information is proprietary
         and confidential to the Affiliates (which information is hereby deemed
         to include, without limitation, all of the types of information
         described in this subparagraph (b)).

         Notwithstanding this subparagraph 14.(b), any information (i) which is
         or becomes available in the public domain through no unlawful or other
         wrongful act

                                      -11-
<PAGE>

         of SeraCare, or (ii) which is publicly announced by the Company or
         generally made available by the Company to other parties, shall be
         excluded from the definition of Proprietary and Confidential
         Information referenced herein.

     (c) SeraCare agrees that it will disclose Proprietary and Confidential
         Information only to its responsible personnel with a bona fide need to
         know and, in such event, to each such person limited to that portion of
         the Proprietary and Confidential Information that each such person
         needs to know. Each such person shall be bound by the terms of this
         paragraph 14, as well as the terms of any separate nondisclosure
         agreement between the person in question and SeraCare. SeraCare shall
         in all events, however, be and remain responsible and liable for
         assuring compliance by SeraCare's personnel with the terms and
         conditions of this paragraph and the other terms and conditions of this
         Agreement.

     (d) SeraCare further agrees that any information it develops or compiles in
         performing its services hereunder which is Proprietary and Confidential
         Information as defined above, and all other Proprietary and
         Confidential Information shall be or is, as the case may be, and shall
         at all times be and remain the sole and exclusive property of Company
         and that all physical reproductions of any nature pertaining to any
         Proprietary and Confidential Information, including, but not limited
         to, electronic medium, memoranda, notebooks, notes, data sheets and
         records, and any and all copies of the same, shall be surrendered to
         the Company immediately upon the termination of this Agreement (whether
         this Agreement expires by its terms or is terminated by Company, by
         SeraCare or by mutual consent, and for whatever reason).

     (e) The obligations of SeraCare contained in this paragraph 14 are separate
         and distinct from and are in addition and cumulative to its obligations
         contained in paragraph 16.

    15. Notification of Unauthorized Disclosure. SeraCare agrees to immediately
notify the Company of any information which comes to SeraCare's attention which
indicates that there has been any improper use or disclosure or any other loss
of confidentiality of any Proprietary and Confidential Information, and upon
discovery of such information or of any unauthorized use or communication of any
Proprietary and Confidential Information, SeraCare shall take such steps as are
necessary or appropriate to prevent any further use or communication of the
information and shall otherwise fully cooperate with the Company in this regard.

    16.  Noncompetition.

     (a) As further consideration for this Agreement, SeraCare covenants and
         agrees that during the term of this Agreement and for a period of five
         (5) years thereafter (whether this Agreement is terminated by the
         Company, by SeraCare or by mutual consent, and for whatever reason),
         SeraCare will not, directly or indirectly,

         (i)   engage in, or

                                      -12-
<PAGE>

         (ii)  become an investor in, or joint venturer with, any individual,
               person, proprietorship, partnership, limited partnership, limited
               liability company, joint venture, corporation, association or
               other entity of any nature which is engaged in the manufacture of
               Bovine Serum Albumin.

     (b) SeraCare and Company expressly acknowledge and agree that it is not
         possible to limit the noncompetition covenants set forth in this
         paragraph 16 to specific persons or entities, or to any specific
         location or geographic area, and that such a limitation would prevent
         the Company from adequately protecting its justifiable business
         interests and frustrate the intent of the Company and SeraCare as to
         this paragraph 16 because, without limitation: (i) Company or its
         Affiliates currently compete for and perform work and services related
         to their respective business throughout substantially all of the United
         States, Canada, Europe, the Pacific Rim countries and South America;
         (ii) the Company or its Affiliates have undertaken and will undertake
         to expand their respective business throughout the Territory; and (iii)
         the nature of the Company's and its Affiliates' business is such that
         competitive activity harmful to the Company or its Affiliates could be
         engaged in by SeraCare regardless of SeraCare's domicile or location.
         SeraCare and the Company further expressly acknowledge and agree that
         the applicability of the noncompetition covenant contained in this
         paragraph 16 to the Affiliates of the Company, and all of the other
         provisions hereof referencing Affiliates, are necessary and appropriate
         because the parties contemplate that the services to be provided by
         SeraCare to the Company under this Agreement may from time to time
         involve or relate to the business conducted by the Affiliates of
         Company.

     (c) SeraCare expressly acknowledges, agrees and warrants to the Company and
         its Affiliates and all third parties that the covenants contained in
         this paragraph 16 are reasonable and consistent with the rights of the
         Company and its Affiliates to protect their business, and are not to be
         held invalid or unenforceable because of the scope of the area, actions
         subject hereto or restricted hereby, or the period of time within which
         such restrictions are operative. SeraCare further acknowledges, agrees
         and warrants to the Company, its Affiliates and all third parties that
         enforcement of a remedy by way of injunction shall not prevent SeraCare
         from earning a livelihood or work an undue hardship on SeraCare, and
         that such injunctive relief, as provided for in paragraph 17 below, is
         necessary and appropriate to protect the reasonable business
         expectations and livelihood of the Company and its Affiliates. In the
         event the restrictive covenant contained in this paragraph 16 is deemed
         by a court, notwithstanding the foregoing, to be too broad in terms of
         the scope of the area, actions subject hereto or restricted hereby, or
         the time period within which such restrictions are operative, or
         otherwise, SeraCare expressly authorizes the court to enforce the
         restrictive covenant contained in this paragraph 16 to the full extent
         the court deems reasonable.

                                      -13-
<PAGE>

    17. Injunction. SeraCare agrees that a breach of paragraphs 13, 14 or 16
above shall constitute a material breach of this Agreement for which Company or
its Affiliates (as the case may be) will have no adequate remedy at law.
SeraCare agrees, therefore, that Company's and its Affiliates' remedies upon a
breach or imminent breach of paragraphs 13, 14 or 16 above include, but are not
limited to, the right to preliminary and permanent injunctive relief restraining
SeraCare from any further violation of said paragraphs, as well as an equitable
accounting of all profits or benefits arising out of such breach, in addition to
any other remedies available at law or in equity or otherwise to Company and its
Affiliates. If an injunction is granted upon a breach of paragraph 16 above, it
is the intent of the parties that the five (5) years period provided for in
paragraph 16 shall run from the date such injunction is granted.

    18. Nature of Relationship; Authority of Parties. Nothing contained in this
Agreement and no action taken or omitted to be taken by the Company or SeraCare
pursuant hereto shall be deemed to constitute the Company and SeraCare a
partnership, an association, a joint venture or other entity whatsoever, nor
shall this Agreement be construed to constitute SeraCare (or any personnel of
SeraCare) an employee or agent of the Company or cause the Company to be
responsible in any way for the acts, omissions, debts, liabilities or
obligations of SeraCare (including, without limitation, any liability arising
from any negligent or other acts or omissions of SeraCare in providing any
services hereunder), nor shall either the Company or SeraCare have the authority
to bind the other in any respect whatsoever; it being understood and agreed by
the parties hereto that SeraCare shall be acting as an independent contractor
and not as an agent, partner or employee of the Company for any purpose
whatsoever. SeraCare shall be solely responsible for discharging all obligations
arising in connection with the operation of SeraCare's business, including,
without limitation, compliance with all laws, rules and regulations relating to
income tax, sales tax, social security, unemployment compensation and worker's
compensation. SeraCare acknowledges that it has not relied upon any statements
or other information made or supplied by the Company as to the potential
profitability or success of SeraCare's efforts or the relationship of the
parties under this Agreement, and that SeraCare is executing this Agreement
based solely upon its own investigation, due diligence, knowledge and judgment.

    19. Control and Ownership of SeraCare; SeraCare Liaison. The Company
acknowledges that SeraCare is a public company which is traded on the American
Stock exchange under the symbol SRK and as such the concentration of ownership
is distributed and fluid.

        SeraCare agrees to designate to the Company in writing a representative
of SeraCare through whom all contacts from the Company pursuant to this
Agreement may be made, and such representative shall be deemed to have full
authority to resolve all matters, disputes and issues under this Agreement on
SeraCare's behalf. SeraCare may change such designated representative from time
to time upon sixty (60) days prior written notice to the Company.

    20. Indemnification. In addition to the other indemnities provided for
herein or otherwise available to the Company, SeraCare shall defend, indemnify,
and hold the Company harmless from and against any loss, claim, liability,
damage, cost or expense (including, without limitation, attorney fees and court
costs) arising in connection with or resulting from any negligence or
performance or nonperformance by SeraCare (or any employee, agent or other

                                      -14-
<PAGE>

personnel of SeraCare) hereunder or with or from any breach of warranty,
misrepresentation or nonfulfillment of any agreement on the part of SeraCare (or
any employee, agent or other personnel of SeraCare) under this Agreement.

       In addition to the other indemnities provided for herein or otherwise
available to SeraCare, the Company shall defend, indemnify, and hold SeraCare
harmless from and against any loss, claim, liability, damage, cost or expense
(including, without limitation, attorney fees and court costs) arising in
connection with or resulting from any negligence or performance or
nonperformance by the Company (or any employee, agent or other personnel of the
Company) hereunder or with or from any breach of warranty, misrepresentation or
nonfulfillment of any agreement on the part of the Company (or any employee,
agent or other personnel of the Company) under this Agreement.

    21. No Waiver; Modifications in Writing. No failure or delay on the part of
any party in exercising any right, power or remedy hereunder shall operate as a
waiver thereof, nor shall any single or partial exercise of any such right,
power or remedy preclude any other or further exercise thereof or the exercise
of any other right, power or remedy. Except as may be otherwise expressly
provided herein, the remedies provided herein are cumulative and are not
exclusive of any remedies that may be available to any party at law or in equity
or otherwise. No amendment, modification, supplement, termination or waiver of
or to any provision of this Agreement, nor consent to any departure therefrom,
shall be effective unless the same shall be in writing and signed by each of the
parties hereto. Any amendment, modification or supplement of or to any provision
of this Agreement, any waiver of any provision of this Agreement, and any
consent to any departure from the terms of any provision of this Agreement,
shall be effective only in the specific instance and for the specific purpose
for which made or given.

     22.  Governing Law; Consent to Jurisdiction; Waiver of Jury Trial.  This
Agreement shall be governed by and construed in accordance with the laws of the
United States of America and the State of Iowa, but without regard to provisions
thereof relating to conflicts of law.  Each of the parties hereby irrevocably
submits to the nonexclusive jurisdiction of any United States Federal Court
sitting in the Southern District of Iowa, Central District, or Iowa District
Court sitting in Nevada, Iowa, in any action or proceeding arising out of or
relating to this Agreement, and each party hereby irrevocably agrees that all
claims with respect to any such action or proceeding may be heard and determined
in any such United States Federal or Iowa District Court.  Each of the parties
irrevocably waives any objection, including, without limitation, any objection
to the laying of venue or based on the grounds of forum non conveniens, which it
may now or hereafter have to the bringing of such action or proceedings in such
respective jurisdictions.  Each of the parties irrevocably consents to the
service of any and all process in any such action or proceeding brought in any
court in and of the State of Iowa by the delivery of copies of such process to
each party, at its address specified for notices to be given hereunder, or by
certified mail direct to such address.  EACH OF THE PARTIES WAIVES ANY RIGHT TO
A JURY TRIAL WITH RESPECT TO ANY CLAIM, COUNTERCLAIM OR ANY OTHER DEMAND OR
MATTER WHATSOEVER ARISING OUT OF THIS AGREEMENT.

    23. Force Majeure. No party shall be liable to the other for failure or
delay in the performance of any of it obligations under this Agreement for the
time and to the extent such

                                      -15-
<PAGE>

failure or delay is caused by earthquake, riot, civil commotion, war,
hostilities between nations, governmental law, order, rule or regulation,
embargo, action by the government or any agency thereof, act of God, storm,
fire, accident, labor dispute or strike, sabotage, explosion or other similar or
different contingencies, in each case, beyond the reasonable control of the
respective party ("Force Majeure"). The party affected by Force Majeure shall
provide the other party with full particulars thereof as soon as it becomes
aware of the same (including its best estimate of the likely extent and duration
of the interference with its activities).

    24. Miscellaneous. This Agreement may not be assigned, in whole or in part,
by either party hereto without the prior written consent of the other party.
Both parties hereby agree that such written consent shall not be unreasonably
withheld. In the event of assignment of this Agreement by either party hereto,
all of the terms, covenants and conditions of this Agreement shall remain in
full force and effect, and both parties shall remain liable and responsible for
the due performance of all of the terms, covenants and conditions of this
Agreement which it is obligated to observe and perform.

     During the term of this Agreement, the Company and SeraCare will have
telephonic and/or in-person conferences no less frequently than quarterly, at
which conferences SeraCare's customers for the Products (and the quantities of
Products purchased by such customers) will be identified and reviewed by the
parties hereto.

     The titles or captions of sections and paragraphs in this Agreement are
provided for convenience of reference only and shall not be considered a part
hereof for purposes of interpreting or applying this Agreement, and such titles
or captions do not define, limit, extend, explain or describe the scope or
extent of this Agreement or any of its terms or conditions.

     This Agreement shall not be construed more strongly against any party,
regardless of who was more responsible for its preparation.

     This Agreement may be executed in any number of counterparts, each of which
shall be deemed an original but all of which together shall constitute one and
the same instrument, and in making proof hereof, it shall not be necessary to
produce or account for more than one such counterpart.

     Words and phrases herein shall be construed as in the singular or plural
number and as masculine, feminine or neuter gender, according to the context.

     This Agreement shall be binding upon and shall inure to the benefit of the
parties hereto and their respective heirs, successors, legal representatives and
permitted assigns.  Nothing in this Agreement, express or implied, is intended
to confer upon any party other than the parties hereto and the Company's
Affiliates (and their respective heirs, successors, legal representatives and
permitted assigns) any rights, remedies, liabilities or obligations under or by
reason of this Agreement.

     Any notice or demand desired or required to be given hereunder shall be in
writing and deemed given when personally delivered or when deposited in the
United States mail, postage prepaid, sent certified or registered, and addressed
as follows:

                                      -16-
<PAGE>

     (a)  If to the Company, to:

          AMPC, Inc.
          2325 North Loop Drive
          Ames, IA 50010
          Attention: President
          Facsimile telephone number: (515) 296-7110

     (b)  If to SeraCare, to:

          SeraCare, Inc.
          1935 Avenida del Oro
          Suite F
          Oceanside, California 92056
          Attention: President
          Facsimile telephone number: (760) 806-8933

or to such other address or person as hereafter shall be designated in writing
by the applicable party.

    25. Authority. Each person signing below represents that such person has
been and is authorized and empowered to execute and deliver this Agreement on
behalf of the party on whose behalf the person is executing this Agreement.

    26. Entire Agreement. This Agreement and all exhibits and schedules hereto
constitute the entire agreement between the parties hereto pertaining to the
subject matters hereof, and supersede all negotiations, preliminary agreements
and all prior or contemporaneous discussions and understandings of the parties
hereto in connection with the subject natters hereof. All exhibits and schedules
are incorporated into this Agreement as if set forth in their entirety and
constitute a part hereof.

                                      -17-
<PAGE>

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first above written.

SERACARE, INC.                          AMPC, INC.

By: /s/ Michael F. Crowley II           By: /s/ Michael Budnick
    -------------------------               ---------------

Title: Vice President Operations        Title: Business Development Manager
       -------------------------               - Biologics
                                               ----------------------------

                                      -18-
<PAGE>

                              Schedule of Exhibits

Schedule 1 - Description of Products and Specifications

Schedule 2 - List of Excluded Customers

Schedule 3 - ***

Schedule 4 - List of SeraCare's Owners

-----------------------
*** Confidential information omitted and filed separately with the Securities
and Exchange Commission.

                                      -19-
<PAGE>

Schedule 1:  Description of Products and Specifications

AMPC Inc.'s Bovine Serum Albumin (BSA) is a high purity protein derived from the
plasma of US-origin healthy animals.  The material is initially fractionated by
a modified, proprietary heat-shock method, and is further isolated from other
plasma components by a unique, non-solvent procedure.  Typical purity levels are
in excess of 98%.

AMPC Inc.'s BSA is sourced exclusively through long-term relationships with
stable mid-western USA abattoirs, and the products are manufactured in the
United States.  The animals receive ante- and post-mortem inspection under a
USDA veterinarian's supervision and are certified apparently free of infectious
diseases and injurious parasites.  The raw material is not commingled with any
other animal-derived tissues, and is subjected to a pH of less than 5 and a
temperature of greater than 65 degrees C for at least three hours during the
manufacturing process. BSE is not known to exist in the USA.

***

Schedule 2

***

Schedule 3:

                                     ***

BSA Standard Grade Powder            ***

BSA Standard Grade Powder, pH 5.2    ***

BSA Cohn Analog Powder               ***

BSA Reagent Grade Powder             ***

Schedule 4:  List of SeraCare's Owners

SeraCare is a public company with approximately 8.0 million shares issued and
outstanding.  SeraCare is traded on the American Stock Exchange under the symbol
SRK.

-----------------------
*** Confidential information omitted and filed separately with the Securities
and Exchange Commission.

                                      -20-<PAGE>

                                                                   Exhibit 10.13

                         SUPPLY AND SERVICES AGREEMENT

          This Supply and Services Agreement (this "Agreement") is entered into
as of August 29, 2001, by and between SeraCare, Inc., a Delaware corporation
("SeraCare"), and SeraCare Life Sciences, Inc., a California corporation and
wholly-owned subsidiary of SeraCare ("Life Sciences").  SeraCare and Life
Sciences are sometimes referred to herein individually as a "party" or
collectively as the "parties."

                                   RECITALS

          WHEREAS, SeraCare has entered into an Agreement and Plan of Merger
(the "Merger Agreement") with Instituto Grifols, S.A., a company organized under
the laws of Spain ("Grifols"), pursuant to which SeraCare will merge with and
into SI Merger Corp., a Delaware corporation and wholly-owned subsidiary of
Grifols (the "Merger"), provided that all of the conditions precedent to the
Merger set forth in the Merger Agreement have been satisfied;

          WHEREAS, the parties have determined that it is appropriate and
desirable to distribute to the holders of SeraCare's common stock, by means of a
pro rata distribution immediately prior to the effective time of the Merger, all
of the shares of Life Sciences common stock (the "Distribution");

          WHEREAS, the parties desire to set forth herein terms and conditions
pursuant to which SeraCare agrees to supply, and Life Sciences agrees to
purchase and accept, certain plasma products, and SeraCare agrees to perform
certain plasmapheresis services on referred donors, and Life Sciences agrees to
purchase and accept such referred donor plasma, following the Distribution.

          NOW, THEREFORE, in consideration of the foregoing and the mutual
covenants and agreements set forth below, the parties, intending to be legally
bound, hereby agree as follows:

     1.  Products, Services Prices and Payment
         -------------------------------------

          1.1  Life Sciences agrees to purchase from SeraCare, and SeraCare
agrees to sell to Life Sciences, plasma-related products (the "Products") set
forth on Exhibit A attached hereto at such prices as set forth on Exhibit A.
         -------                                                          -
Life Sciences and SeraCare represent and warrant that such prices were
determined as a result of arms-length negotiation between the parties. The
parties shall negotiate annually in good faith mutually acceptable price
adjustments (increase or decrease) of the Products based on factors the parties
deem relevant including the then prevailing market price for such products,
regulatory issues and testing requirements. Such price adjustment shall be
effective upon each anniversary of the initial, or any renewal term, of this
Agreement, provided that in the event that there are changes in any legal or
regulatory requirements that materially impact SeraCare's costs of the Product
production, the parties shall, prior to such annual negotiations, negotiate in
good faith price increases or decreases not to exceed the direct costs of such
change in legal or regulatory requirements, provided further that in no event
shall the price for the Products exceed the fair market value for the Products.
If the
<PAGE>

parties are unable to reach agreement on an annual price adjustment as
provided for herein, then the parties shall submit the matter to dispute
resolution as provided for in Section 8.5.

          1.2  Subject to Life Sciences' Standard Operating Procedures and any
applicable requirements relating to a subject donor's medical condition,
SeraCare agrees it shall (i) perform automated plasmapheresis bleedings on all
donors referred by Life Sciences (the "Plasmapheresis Services"), and that Life
Sciences shall have the right to receive all blood plasma collected by SeraCare
which is derived from such referred donors (the "Referred Donor Plasma"), and
(ii) if and when SeraCare acquires an appropriately licensed and equipped
center, draw blood on all donors referred by Life Sciences (the "Blood Drawing
Services"), and that Life Sciences shall have the right to receive all whole
blood, off the clot, serum, et. al. therefrom (the "Referred Donor Blood,"
collectively, with the Referred Donor Plasma, the "Referred Donor Products.")
SeraCare shall conduct viral marker testing and FDA required confirmatory
testing on all Referred Donor Products (the "Testing Services"). The price,
including softgoods, (but excluding donor fees which shall be payable by Life
Sciences) for such Plasmapheresis Services, Blood Drawing Services, Testing
Services and Referred Donor Products (collectively, the "Referred Donor
Services") shall be as set forth on Exhibit A , as amended from time to time in
accordance with this Agreement. Life Sciences and SeraCare represent and warrant
that such prices were determined as a result of arms-length negotiation between
the parties. The parties shall negotiate annually in good faith mutually
acceptable price adjustments (increase or decrease) of the Referred Donor
Services based on factors the parties deem relevant including the then
prevailing market price for such products, regulatory issues and testing
requirements. Such price adjustment shall be effective upon each anniversary
date of the initial, or any renewal term, of this Agreement, provided that in
the event that there are changes in any legal or regulatory requirements that
materially impact SeraCare's costs of the Referred Donor Services, the parties
shall, prior to such annual negotiations, negotiate in good faith price
increases or decreases not to exceed the direct costs of such change in legal or
regulatory requirements, provided further that in no event shall the price for
the Referred Donor Services exceed the fair market value for the Referred Donor
Services. If the parties are unable to reach agreement on an annual price
adjustment as provided for herein, then the parties shall submit the matter to
dispute resolution as provided for in Section 8.5.

          1.3  Payment by Life Sciences for any Products will be made within
thirty (30) days from date of delivery of such Products by SeraCare, and payment
by Life Sciences for any Referred Donor Services will be made within thirty (30)
days from the date of delivery of the Referred Donor Products by SeraCare.

          1.4  All costs of shipment, freight, insurance and all government
taxes and duties incurred in connection with shipment of the Products and the
Referred Donor Products to Life Sciences or Life Sciences customers will be paid
by Life Sciences.

          1.5  Life Sciences agrees that it shall exclusively use the
appropriately licensed Centers (as hereinafter defined) for donors in respect of
Referred Donor Services for all donors who reside within reasonable proximity to
an appropriately licensed Center.

     2.  Delivery, Storage and Handling
         ------------------------------

                                      -2-
<PAGE>

          2.1  All Products and Referred Donor Products will be packed and
shipped in accordance with SeraCare's established Standard Operating Procedures
that significantly relate to the collection of blood plasma in effect as of the
date hereof, as may be amended from time to time as provided for in Section 3.1,
and all applicable sections of the Code of Federal Regulations, including all
applicable sections and regulations issued or promulgated by the United States
Food and Drug Administration, as well as any other applicable federal, state,
and local regulations concerning the collection, packaging, processing, storing
or shipping of the Products. All shipments of the Products and Referred Donor
Products will contain all duly and properly prepared documentation required by
applicable laws or regulations.

          2.2  Life Sciences shall deliver to SeraCare a purchase order with the
specifications of each order of the Products.

          2.3  Title and all risk of loss and damage regarding the Products and
the Referred Donor Products shall pass to Life Sciences upon delivery to Life
Sciences, except for Products or Referred Donor Products rejected pursuant to
Section 3.3.

          2.4  Life Sciences agrees that upon delivery of Products and Referred
Donor Products to Life Sciences, Life Sciences shall handle, store and maintain
all Products and Referred Donor Products in an appropriate environment in
accordance with applicable law, industry standards and good manufacturing
practices. If Life Sciences shall fail to handle, store and maintain any
Products or Referred Donor Products in accordance with this Agreement, such
Products or Referred Donor Products shall not be subject to rejection as
provided below. Life Sciences shall indemnify SeraCare pursuant to Section 8.1
hereof in the event that any third-party claims arise because of any failure by
Life Sciences to handle, store and maintain Products or Referred Donor Products
in accordance with this Agreement.

     3.   Product Quality and Use
          -----------------------

          3.1  All Products sold to Life Sciences hereunder shall conform to the
quality and technical specifications set forth for such Products on Exhibit B
                                                                    ---------
attached hereto (the "Minimum Specifications"), provided that SeraCare may
modify its Standard Operating Procedures (which are included in the Minimum
Specifications) only if such modification (i) relates solely to a change
required by law (based on the advice of nationally recognized healthcare
regulatory counsel) and SeraCare notifies Life Sciences of such modification at
least five business days prior to the effective date of such modification, (ii)
does not significantly relate to the collection of blood plasma, or (iii) is not
required by law (based on the advice of nationally recognized healthcare
regulatory counsel) and SeraCare has obtained written consent of such change
from Life Sciences. In addition, SeraCare agrees that the Products delivered to
Life Sciences shall not be misbranded or adulterated within the meaning of the
Federal Food, Drug and Cosmetic Act, and shall be in full compliance with the
Biological Products Section of the Public Health Service Act, and applicable
regulations, and shall be in full compliance with any applicable international,
federal, state or local laws, ordinances or regulations in accordance with past
practice. Subject to Section 8.14 hereof, in the event SeraCare ships to Life
Sciences any Products which are not in compliance with such laws, regulations or
the Minimum Specifications, then SeraCare will be liable to Life Sciences for
damages arising out of relating

                                      -3-
<PAGE>

to such non-compliant Products (including, without limitation, attorneys fees,
arbitrators' fees, costs of experts and court costs).

          3.2  All Referred Donor Services performed hereunder shall conform to
the quality and technical specifications set forth for such Referred Donor
Services on Exhibit C attached hereto (the "Referred Donor Minimum
            ---------
Specifications"), provided that Life Sciences may modify the Minimum
Specifications upon written notification to SeraCare with such modifications to
be effective within five (5) business days of delivery of such notification. In
addition, SeraCare agrees that the Referred Donor Products delivered to Life
Sciences shall not be misbranded or adulterated within the meaning of the
Federal Food, Drug and Cosmetic Act, and shall be in full compliance with the
Biological Products Section of the Public Health Service Act, and applicable
regulations, and shall be in full compliance with any applicable international,
federal, state or local laws, ordinances or regulations in accordance with past
practice. Subject to Section 8.14 hereof, in the event SeraCare ships to Life
Sciences any Referred Donor Products which is not in compliance with such laws,
regulations or the Referred Donor Minimum Specifications, then SeraCare will be
liable to Life Sciences for damages arising out of relating to such non-
compliant Referred Donor Products (including, without limitation, attorneys
fees, arbitrators' fees, costs of experts and court costs).

          3.3

          (A)  All Referred Donor Products furnished by SeraCare to Life
Sciences hereunder which does not meet the Referred Donor Minimum
Specifications, and all Products furnished by SeraCare to Life Sciences
hereunder which do not meet the Minimum Specifications, or which are, in Life
Sciences' reasonable judgment, otherwise defective shall be subject to rejection
notwithstanding prior payment by Life Sciences, provided that any rejection of
Referred Donor Products or Products, other than de minimis rejections, shall be
accompanied by a written explanation from Life Sciences setting forth the basis
or bases for such rejection. SeraCare acknowledges and agrees that Life Sciences
may reject any Products that do not conform to the Minimum Specifications, or
any Referred Donor Products that does not conform to the Referred Donor Minimum
Specifications, at any time up to thirty (30) business days after delivery of
such Products or Referred Donor Products to Life Sciences or Life Sciences
customers, provided that any Products or Referred Donor Products not rejected
during such period shall be deemed to be accepted by Life Sciences.

          (B)  Subject to Section 2.4 and 8.14 hereof, Life Sciences shall have
no liability whatsoever with respect to such rejected Products or Referred Donor
Products and SeraCare shall reimburse Life Sciences for any and all costs and
expenses (including but not limited to shipment, freight, insurance and all
government taxes and duties incurred during shipment, transportation, storage,
handling and pooling costs) which are incurred by Life Sciences with respect to
any such rejected Products or Referred Donor Products. SeraCare shall have the
right to instruct Life Sciences to (i) return any rejected Products or Referred
Donor Products to SeraCare (after receiving notification of such rejection) or
(ii) destroy such rejected Products or Referred Donor Products in lieu of
returning them to SeraCare, provided that Life Sciences shall use its best
efforts to dispose of such rejected Products or Referred Donor Products in
accordance with all applicable law and regulations. In the event SeraCare does
not give instructions regarding the disposition of such rejected Products or
Referred Donor Products

                                      -4-
<PAGE>

within fifteen (15) business days after notice of rejection of the Products or
Referred Donor Products by Life Sciences to SeraCare, Life Sciences shall have
the right to destroy or otherwise dispose of all such rejected Products or
Referred Donor Products at SeraCare's sole expense without any liability
whatsoever to SeraCare and without obligation to compensate SeraCare for any
part of such rejected Products or Referred Donor Products.

          3.4  Subject to the terms and conditions contained herein, including
without limitation the liability limitation in Section 8.14, in the event Life
Sciences makes prior payment for Products or Referred Donor Products which are
later rejected in accordance with this Agreement, the purchase price of such
rejected Products or Referred Donor Products, and any other costs and expenses
incurred by Life Sciences in connection with such rejected Products or Referred
Donor Products, may be set off or deducted from any other payments due to
SeraCare from Life Sciences. In addition, Life Sciences shall have the right, at
its sole election, to demand reimbursement, in cash, for the purchase price and
any other sums paid in connection with any such rejected Products or Referred
Donor Services, subject to SeraCare's right to set off or deduct payments due
from Life Sciences.

          3.5  Life Sciences represents and warrants to SeraCare that the
Products and the Referred Donor Products shall be manufactured and distributed
solely for diagnostic purposes and not for human consumption or otherwise for
injection into humans.

     4.  Regulatory Requirements
         -----------------------

         4.1  SeraCare represents and warrants that as of the date of this
Agreement, each of the centers set forth on Exhibit D attached hereto, as
                                            ---------
amended from time to time in accordance herewith, (the "Centers" or individually
a "Center") is Licensed as hereinafter defined. For purposes of this Agreement,
a Center is Licensed when it has (i) a license issued by the United States Food
and Drug Administration (the "FDA"); (ii) is Quality Plasma Program ("QPP")
certified, and (iii) has all other material permits and licenses which are
required by federal, state or local regulatory agencies in order for SeraCare to
operate the Centers, except for the Centers located in Danville, Virginia and
Providence, Rhode Island, for which SeraCare agrees to use its best efforts to
obtain QPP certification. SeraCare agrees that all of the Products sold by
SeraCare to Life Sciences hereunder will be collected only at the Centers, and
all of the Referred Donor Services will be performed only at the Centers.
SeraCare shall immediately notify Life Sciences if any Center is no longer
Licensed, and the parties expressly agree that any Center that is no longer
Licensed will be deleted from Exhibit D.

         4.2  SeraCare agrees that it shall operate the Centers in material
compliance with applicable federal, state and local laws, rules and regulations.
SeraCare also agrees to be solely responsible for ensuring that its Centers
materially comply with laws, rules and regulations pertaining to occupational
safety and health, blood borne pathogens and good manufacturing practices.

         4.3  If at any time during the term of this Agreement SeraCare receives
written notice (a "Compliance Notice") from any federal, state or local
governmental entity or agency that any Center is out of compliance in any
material respect with applicable federal, state or local laws, rules or
regulations, SeraCare agrees that it will inform Life Sciences within five (5)

                                      -5-
<PAGE>

business days of its receipt of such written notification. For purposes hereof,
a FDA Form 483 notice or similar inspection report shall be deemed to be a
Compliance Notice. Within thirty (30) days after notifying Life Sciences of such
non-compliance, SeraCare shall deliver written notice informing Life Sciences of
its election either to (i) remove the non-compliant Center from Exhibit D, or
(ii) provide Life Sciences with a written proposal in which SeraCare sets forth
the commercially reasonable efforts that it will use to, and projected timetable
within which it will, bring the non-compliant Center into material compliance.
If SeraCare elects to try to bring a non-compliant Center into material
compliance and satisfies the concerns of the subject governmental entity or
agency enumerated in the Compliance Notice, or, six months after responding to
such Compliance Notice, SeraCare has received no further correspondence from the
subject governmental entity in respect thereof, the Center which is the subject
of such Compliance Notice shall be deemed to be in compliance with this
Agreement and shall not be removed from Exhibit D. If SeraCare elects to try to
bring a non-compliant Center in to material compliance but is unsuccessful, in
the reasonable determination of Life Sciences, in bringing such center into
material compliance herewith and with such Compliance Notice within thirty (30)
days of the date of delivery of the written proposal referred to in clause (ii)
of this Section 4.3, either party notify the other that it elects to remove the
non-compliant Center from Exhibit D, and that Center's removal will be effective
immediately upon delivery of that notice.

          4.4  The parties further agree that Life Sciences has the right to
inspect any Center on 24 hours' notice and at Life Sciences' sole expense during
normal business hours to ensure material compliance with applicable regulations.
Life Sciences agrees to conduct such inspection in a reasonable manner. If
SeraCare receives from Life Sciences a notice of non-compliance resulting from
the inspection, within thirty (30) days of receipt of such notice of such non-
compliance, SeraCare shall deliver written notice informing Life Sciences of its
election either to (i) remove the non-compliant Center from Exhibit D, or (ii)
provide Life Sciences with a written proposal in which SeraCare sets forth the
commercially reasonable efforts that it will use to, and projected timetable
within which it will, bring the non-compliant Center into material compliance.
If SeraCare elects to try to bring a non-compliant Center in to material
compliance, and the relevant remediation efforts cause the Center to be able to
produce Products or collect Referral Donor Products in accordance with the
Minimum Specifications, or Referred Donor Minimum Specifications, as the case
may be, and the Center is otherwise in compliance with all applicable laws and
regulations, the Center which is the subject of the non-compliance shall be
deemed to be in compliance with this Agreement and shall not be removed from
Exhibit D. If SeraCare elects to try to bring a non-compliant Center into
material compliance but is unsuccessful, in the reasonable determination of Life
Sciences, within thirty (30) days from the date of delivery of the written
proposal referred to in clause (ii) of this Section 4.4, either party notify the
other that it elects to remove the non-compliant Center from Exhibit D, and that
Center's removal will be effective immediately upon delivery of that notice.

     5.   Access to Donor Base
          --------------------

          Subject to applicable laws and regulations regarding the
confidentiality of donor information, SeraCare agrees that it shall grant Life
Sciences continuing access during the term of this Agreement to its donor base
of all donors who signed a consent form to allow donor history to be included in
the database, (the "consented donor base") including donor history files. The
parties acknowledge that as of the date of this Agreement to their knowledge and
after

                                      -6-
<PAGE>

reasonable investigation HIPAA does not apply to SeraCare and the donor
information provided to Life Sciences pursuant to this Agreement. SeraCare shall
provide Life Sciences such information in a reasonable format requested by Life
Sciences within a reasonable time period, which in no event shall exceed five
(5) business days from the date of the request.

     6.   Warrant
          -------

          Immediately following the Distribution, Life Sciences shall grant
Instituto Grifols, S.A., or its affiliate, a warrant, in accordance with the
terms of the Warrant Agreement attached hereto as Exhibit E, to purchase up to
                                                  ----------
ten (10) percent of the outstanding common stock of Life Sciences immediately
following the Distribution, which, for purposes of example, if calculated as of
the date hereof (assuming conversion of the warrants issued to by SeraCare to
Nap & Co., Fuelship & Co., Northman & Co., and Hare & Co.) would be 1,388,962
shares of common stock of Life Sciences.

     7.   Term and Termination
          --------------------

          7.1  Term.  The term of this Agreement shall commence immediately
               ----
following the Distribution and shall continue until January 24, 2006, unless
earlier terminated or extended as provided herein. This Agreement shall
automatically terminate and be of no further force and effect in the event the
Merger Agreement is terminated.

          7.2  Termination.

          (A)  Upon the occurrence of any of the following events, Life Sciences
shall be entitled to (a) receive immediate written notice of the occurrence of
such event and (b) terminate this Agreement immediately by giving written notice
of termination to SeraCare:

               (1)  In the event of insolvency of SeraCare or in the event that
in involuntary or voluntary petition in bankruptcy is filed by, against or on
behalf of SeraCare;

               (2)  In the event SeraCare makes a general assignment for the
benefit of its creditors, or a receiver or trustee is appointed for its business
or property;

               (3)  In the event three (3) or more Centers materially fail any
inspection by Life Sciences, the FDA or any applicable federal, state or local
government agency in any twelve month period, and the circumstances giving rise
to such inspection is not cured as contemplated by Section 4; or

               (4)  In the event SeraCare fails to observe the terms of this
Agreement and such failure shall continue to exist for thirty days after written
notice of such failure has been given to SeraCare.

          (B)  Upon the occurrence of any of the following events, SeraCare
shall be entitled to (a) receive immediate written notice of the occurrence of
such event and (b) terminate this Agreement immediately by giving written notice
of termination to Life Sciences:

                                      -7-
<PAGE>

               (1)  In the event of insolvency of Life Sciences or in the event
that in involuntary or voluntary petition in bankruptcy is filed by, against or
on behalf of Life Sciences;

               (2)  In the event Life Sciences makes a general assignment for
the benefit of its creditors, or a receiver or trustee is appointed for its
business or property; or

               (3)  In the event Life Sciences fails to observe the terms of
this Agreement and such failure shall continue to exist for thirty days after
written notice of such failure has been given to Life Sciences.

          (C)  Failure or delay by either party in terminating this Agreement
following the occurrence of any event specified in Section 8.2 (A) or (B) above
or following any other breach of this Agreement shall not constitute a waiver of
such party's right to terminate this Agreement.

          (D)  Subject to Section 8.14 hereof, no termination of this Agreement
shall release or discharge either of the parties from any debt or liability
which shall have been incurred or accrued prior to the date of termination.

          7.3  Renewal.  The first or any subsequent term of this Agreement
               -------
shall automatically be extended for successive renewal terms of one year each in
duration, on the otherwise same terms and conditions, unless either party
provides written notice of intent not to extend to the other party on or at
anytime before four months prior to the expiration of the then current term.

     8.   Miscellaneous
          -------------

          8.1  Indemnification.  Subject to Section 8.14, each party hereto (the
               ---------------
"Indemnifying Party") shall, to the extent of the Indemnifying Party's
proportionate share of fault, if any, indemnify and hold harmless the other
party and its officers, directors, employees, agents, representatives,
contractors and subcontractors from and against any and all claims or causes of
action brought by any third party or third parties arising out of any act or
omission of the Indemnifying Party in connection with this Agreement.

          8.2  Insurance.  SeraCare agrees to carry at its sole cost and
               ---------
expense during the term of this Agreement and for a reasonable time thereafter,
product and professional liability insurance consistent with prudent business
practices in the industry with respect to the Products and Referred Donor
Services in an amount not less than $300,000 per occurrence for product
liability and not less than $500,000 per occurrence for professional liability.
Life Sciences agrees to carry at its sole cost and expense during the term of
this Agreement and for a reasonable time thereafter, product insurance
consistent with prudent business practices in the industry for the Products or
Referred Donor Products in an amount not less than $300,000 per occurrence for
product liability. If SeraCare's product liability or professional liability
insurance is claims-made (rather than occurrence) insurance, then, before this
Agreement expires, SeraCare shall purchase tail insurance covering claims that
arise after the Agreement expires.

          8.3  Confidentiality.  The parties agree to maintain the
               ---------------
confidentiality of the contents of this Agreement. Neither party will
voluntarily disclose the contents of this

                                      -8-
<PAGE>

Agreement. Neither party will voluntarily disclose the contents of this
Agreement unless such disclosure is pre-approved in writing by the other party,
or such disclosure is required by law or governmental regulation.

          8.4  Entire Agreement.  This Agreement constitutes the entire
               ----------------
agreement between the parties with respect to the subject matter hereof and
shall supersede all prior written and oral and all contemporaneous oral
agreements and understandings with respect to the subject matter hereof.

          8.5  Dispute Resolution.  Resolution of any and all disputes, claims
               ------------------
and causes of action of any nature whatsoever (collectively, "Disputes"),
arising from or relating to this Agreement, shall be exclusively governed by the
provisions of this Section 8.5.

          (a)  Negotiation.  The parties shall make a good faith attempt to
               -----------
resolve any Dispute arising out of or relating to this Agreement through
informal negotiation between appropriate representatives from each of SeraCare
and Life Sciences. If at any time either party feels that such negotiations are
not leading to a resolution of the Dispute, such party may send a notice to the
other party describing the Dispute and requesting a meeting of the senior
executives from each party. Within ten (10) Business Days after such notice is
given, each party shall select appropriate senior executives of each party who
shall have the authority to resolve the matter and shall meet to attempt in good
faith to negotiate a resolution of the Dispute. During the course of
negotiations under this Section 8.5(a), all reasonable requests made by one
party to the other for information, including requests for copies of relevant
documents, will be honored. The specific format for such negotiations will be
left to the discretion of the designated negotiating senior executives but may
include the preparation of agreed upon statements of fact or written statements
of position furnished to the other party. In the event that any Dispute arising
out of or related to this Agreement is not settled by the parties within thirty
(30) days after the first meeting of the negotiating senior executives, either
party may submit the Dispute to arbitration pursuant to Section 8.5(b).

          (b)  Arbitration.  All Disputes not resolved by good faith
               -----------
negotiations among the parties pursuant to Section 8.5(a) within the prescribed
time period shall be submitted to, and determined by, arbitration. Such
arbitration shall proceed in accordance with the then-current rules for
arbitration established by the American Arbitration Association ("AAA"), unless
the parties hereto mutually agree otherwise, and pursuant to the following
procedures:

               (i)    The parties shall attempt in good faith to select from the
     AAA panel one (1) arbitrator mutually acceptable to both parties sitting in
     the state of New York. If the parties fail to agree upon an arbitrator
     within fifteen (15) calendar days, an arbitrator shall be selected by AAA
     in pursuant to the procedures set forth in AAA Rules. The parties agree
     that for disputes involving $1 million or more exclusive of claimed
     interest, arbitration fees and costs, the procedures for "large complex
     commercial disputes" of the AAA shall apply. In the event of a conflict,
     the provisions of this Agreement will control.

               (ii)   Reasonable discovery shall be allowed in arbitration.

                                      -9-
<PAGE>

               (iii)  All proceedings before the arbitrator shall be held in New
     York, New York. The governing law shall be that of California.

               (iv)   The award rendered by the arbitrator shall be final and
     binding, and judgment may be entered in accordance with applicable law and
     in any court having jurisdiction thereof.

               (v)    The award rendered by the arbitrator shall include (A) a
     provision that the prevailing party in such arbitration recover its costs
     relating to the arbitration and reasonable attorneys' fees from the other
     party, (B) the amount of such costs and fees, and (C) an order that the
     losing party pay the fees and expenses of the arbitrator.

               (vi)   The arbitrator shall by the agreement of the parties
     expressly be prohibited from awarding punitive damages in connection with
     any claim being resolved by arbitration hereunder.

               (vii)  All aspects of the arbitration shall be treated as
     confidential. Neither the parties nor the arbitrator may disclose to any
     third party the existence, content or results of the arbitration, except as
     necessary to enforce the award in court or to comply with legal or
     regulatory requirements.

          8.6  Governing Law.  This Agreement shall be construed in accordance
               -------------
with and all Disputes hereunder shall be governed by the laws of the State of
California, excluding its conflict of law rules.

          8.7  Notice.  Any notice, demand, offer, request or other
               ------
communication required or permitted to be given by either party pursuant to the
terms of this Agreement shall be in writing and shall be deemed effectively
given the earlier of (i) when received, (ii) when delivered personally, (iii)
one (1) business day after being delivered by facsimile (with receipt of
appropriate confirmation), (iv) one (1) business day after being deposited with
an overnight courier service, or (v) four (4) days after being deposited in the
U.S. mail, First Class with postage prepaid, and addressed to the attention of
the party's Chief Executive Officer at the address of its principal executive
office or such other address as a party may request by notifying the other party
thereof in writing.

          8.8  Counterparts.  This Agreement, including other documents
               ------------
referred to herein, may be executed in counterparts, each of which shall be
deemed to be an original but all of which shall constitute one and the same
agreement.

          8.9  Binding Effect; Assignment.  This Agreement shall inure to the
               --------------------------
benefit of and be binding upon the parties hereto and their respective legal
representatives and successors, and nothing in this Agreement, express or
implied, is intended to confer upon any other Person any rights or remedies of
any nature whatsoever under or by reason of this Agreement.  Except as herein
specifically provided to the contrary, neither party may assign this Agreement
or any rights or obligations hereunder, without the prior written consent of the
other party, and any such assignment shall be void; provided, however, either
party (or its permitted successive assignees or transferees hereunder) may
assign or transfer this Agreement as a whole without consent to an

                                      -10-
<PAGE>

entity that succeeds to all or substantially all of the business or assets of
such party to which this Agreement relates.

          8.10  Severability.  The parties hereto have negotiated and prepared
                ------------
the terms of this Agreement in good faith with the intent that each and every
one of the terms, covenants and conditions herein be binding upon and inure to
the benefit of the respective parties. Accordingly, if any one or more of the
terms, provisions, promises, covenants or conditions of this Agreement or the
application thereof to any person or circumstance shall be adjudged to any
extent illegal, invalid, unenforceable, void or voidable for any reason
whatsoever by a court of competent jurisdiction, then the parties agree to
negotiate immediately in good faith to amend the Agreement to preserve to the
maximum extent possible its original provisions. If the parties cannot agree on
an amended agreement within 60 days after the court's ruling, this Agreement
shall immediately terminate.

          8.11  Waiver of Breach.  In order to enforce a waiver of any of this
                ----------------
Agreement's provisions, the enforcing party must have an express, written waiver
from the other party. The waiver by either party hereto of a breach or violation
of any provision of this Agreement shall not operate as, or be construed to
constitute, a waiver of any subsequent breach of the same or another provision
hereof.

          8.12  Amendment and Execution.  This Agreement and amendments hereto
                -----------------------
shall be in writing and executed in multiple copies via facsimile or otherwise
on behalf of SeraCare and Life Sciences by their respective duly authorized
officers and representatives. Each multiple copy shall be deemed an original,
but all multiple copies together shall constitute one and the same instrument.

          8.13  Authority.  Each of the parties hereto represents to the other
                ---------
that (a) it has the corporate or other requisite power and authority to execute,
deliver and perform this Agreement, (b) the execution, delivery and performance
of this Agreement by it have been duly authorized by all necessary corporate or
other actions, (c) it has duly and validly executed and delivered this
Agreement, and (d) this Agreement is a legal, valid and binding obligation,
enforceable against it in accordance with its terms subject to applicable
bankruptcy, insolvency, reorganization, moratorium or other similar laws
affecting creditors' rights generally and general equity principles.

          8.14  Limitation of Liability.

          (A)  IN NO EVENT SHALL EITHER PARTY OR ITS SUBSIDIARIES BE LIABLE TO
THE OTHER PARTY OR ITS SUBSIDIARIES FOR ANY SPECIAL, CONSEQUENTIAL, INDIRECT,
INCIDENTAL OR PUNITIVE DAMAGES OR LOST PROFITS, HOWEVER CAUSED AND ON ANY THEORY
OF LIABILITY (INCLUDING NEGLIGENCE) ARISING IN ANY WAY OUT OF THIS AGREEMENT,
WHETHER OR NOT SUCH OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES.

          (B)  IN NO EVENT SHALL SERACARE OR ITS SUBSIDIARIES BE LIABLE TO LIFE
SCIENCES OR ITS SUBSIDIARIES FOR ANY DIRECT, SPECIAL,

                                      -11-
<PAGE>

CONSEQUENTIAL, INDIRECT, INCIDENTAL OR PUNITIVE DAMAGES OR LOST PROFITS, HOWEVER
CAUSED AND ON ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE) IN THE EVENT THAT
THE PRODUCTS OR REFERRED DONOR PRODUCTS ARE MANUFACTURED FOR OTHER THAN
DIAGNOSTIC PURPOSES, HUMAN CONSUMPTION OR INJECTION INTO HUMANS.

                                      -12-
<PAGE>

          IN WITNESS WHEREOF, each of the parties has caused this Agreement to
be executed on its behalf by its officers thereunto duly authorized on the day
and year first above written.

SERACARE, INC.                           SERACARE LIFE SCIENCES, INC.

By:     /s/ Barry Plost                  By:     /s/ Jerry Burdick
        ---------------                          -----------------
Name:   Barry Plost                      Name:   Jerry Burdick
Title:  President and CEO                Title:  Executive VP and CFO

               [SIGNATURE PAGE TO SUPPLY AND SERVICES AGREEMENT]

                                      -13-
<PAGE>

                           LIST OF OMITTED EXHIBITS

The following Exhibits to the Supply and Services Agreement have been omitted
from this Exhibit and shall be furnished to the Commission upon request:

Exhibit          Document
-------          --------

D                Centers

E                Warrant Agreement

                                      -14-
<PAGE>

                                   EXHIBIT A

                                   Products

<TABLE>
<CAPTION>
------------------------------------------------------------------------------
         Product                         Price
------------------------------------------------------------------------------
<S>                                <C>
Reactive Units                       $50 per unit
------------------------------------------------------------------------------
Orphan Plasma                        $35 per liter
------------------------------------------------------------------------------
Male A/B Plasma                      $120 per liter
------------------------------------------------------------------------------
Antibody Positive Plasma             $120 per liter
------------------------------------------------------------------------------
Antibody Negative Plasma             $120 per liter
------------------------------------------------------------------------------

<CAPTION>
------------------------------------------------------------------------------
Referred Donor Services                  Price
------------------------------------------------------------------------------
<S>                                <C>
Referred Donor Plasma                $200.00 per donor
------------------------------------------------------------------------------
Referred Donor Blood                 $35.00 per donor
------------------------------------------------------------------------------
</TABLE>

                                      -15-
<PAGE>

                                   EXHIBIT B

                            Minimum Specifications

1.   The Products supplied to Life Sciences shall be collected and tested in
     accordance with FDA requirements and shall meet the minimum specifications
     as per FDA source plasma guidelines.

2.   The appearance of the Products shall be non-hemalized and non-lipemic.

3.   SeraCare shall provide Life Sciences age, sex, race and data history of
     donors as reasonably requested and permitted by law.

4.   All Products shall be from Qualified Donors, as defined by the American
     Blood Resources Association (ABRA) Quality Plasma Program.

5.   SeraCare shall follow all SeraCare established Standard Operating
     Procedures in effect as of the date hereof, as may be amended from time to
     time in accordance with Section 3.1 of the Supply and Services Agreement.

                                      -16-
<PAGE>

                                   EXHIBIT C

                     Referred Donor Minimum Specifications

1.   The Products supplied to Life Sciences shall be collected and tested in
     accordance with FDA requirements and shall meet the minimum specifications
     as per FDA source plasma guidelines.

2.   The appearance of the Products shall be non-hemalized and non-lipemic.

3.   SeraCare shall provide Life Sciences age, sex, race and data history of
     donors as reasonably requested and permitted by law.

4.   SeraCare shall follow all Life Sciences established Standard Operating
     Procedures, which have been delivered to SeraCare as of the date hereof,
     and as may be amended from time in the sole discretion of Life Sciences.

                                      -17-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}]]